Form D · Other
Atlas Oncology Holdings Inc.
Nashville, TN · CIK 0002110866
Offering snapshot reported Feb 25, 2026 · SEC filing
- Reported sold
- $23M Offering amount: $23M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2026 | Initial | $23,000,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-574621
Source: Form D, filed Feb 25, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ian Chiang | Director |
| Dave Fielding | Director, Promoter |
| David Glaccum | Director, Executive, Promoter |
| Matt Kim | Director, Promoter |
| Todd Nice | Executive, Promoter |
| Kate Barnard Roberts | Executive, Promoter |
| Tara Sullivan | Director |
Issuer details
Industry: Other (See others in industry)
Address:
1316 Adams Street Suite 400
Nashville, TN, 37208
Nashville, TN, 37208